The present study aimed to investigate the overall changes in exosomal proteomes in metastatic and non-metastatic non-small-cell lung cancers (NSCLC) and healthy human serum samples, and evaluate the potential of serum exosomal biomarkers to predict NSCLC metastasis. Tandem mass tags combined with multidimensional liquid chromatography and mass spectrometry analysis were used for screening the proteomic profiles of serum samples. Quantitative proteome, significant pathway, and functional categories of patients with metastatic and non-metastatic NSCLC and healthy donors were investigated. In total, 552 proteins of the 628 protein groups identified were quantified. Bioinformatics analysis indicated that quantifiable proteins were mainly involved in multiple biological functions, metastasis-related pathways. Moreover, lipopolysaccharide-binding proteins (LBP) in the exosomes were found to be well distinguished between patients with metastatic and patients with non-metastatic NSCLC. Area under the curve (AUC) was 0.803 with a sensitivity of 83.1% and a specificity of 67% (P < .0001). Circulating LBP were also well distinguishable between metastatic and non-metastatic NSCLC, the AUC was 0.683 with a sensitivity of 79.5% and a specificity of 47.2% (P = .005). This novel study provided a reference proteome map for metastatic NSCLC. Patients with metastatic and non-metastatic NSCLC differed in exosome-related proteins in the serum.
extremely vulnerable to relapse and mortality, and the overall 5-year survival rate still remains at 10%-15% as a result of the delay in diagnosing the disease. 4 Still, diagnosing NSCLC can be challenging, and new methods to support the already used clinical tools are needed to secure a better overall outcome. 5 Recently, this field has been enlivened with the exciting possibility that a newly described mode of intercellular cross-talk mediated by exosomes could have important and multifarious roles in local and distant failures, hence opening new possibilities for diagnostic, predictive approaches. 6 Exosomes are secreted membrane-enclosed vesicles (extracellular vesicles) of 50-150 nm in diameter. 7 They are formed during the inward budding of late endosomes, develop into intracellular multivesicular endosomes, and contain functional proteins, RNA molecules, and lipids. [8] [9] [10] They are released by cells and participate in cell-to-cell communication. 11 Exosome-enriched proteins include members of the tetraspanin family (CD9, CD63, and CD81), members of the endosomal sorting complexes required for transport (TSG101 and Alix), and heat-shock proteins (Hsp60, Hsp70, and Hsp90). 12 Recently, TDE have been shown to promote cancer progression, allowing the distal organ site to be prepared as a premetastatic niche. 13, 14 Researchers have proposed that TDE provide autocrine and paracrine signals within the tumor ecosystem to activate an epithelial-mesenchymal transition program in neoplastic epithelial cells. [15] [16] [17] [18] Evidence that exosomes may bias metastatic efficiency to different target organs derives from exosomes' avidity for specific recipient cells. 6, [19] [20] [21] Moreover, TDE are readily available in blood samples where they constitute potential biomarkers of tumor. 5 TDE contain several tumor-associated proteins, such as EGFR, KRAS, and RAB-family proteins. 22 Exosomal proteins may well reflect pathological processes associated with disease. 23 Isolation of exosomes and their use in the clinic may substitute invasive procedures for diagnosis or the follow up of cancer patients, mainly in NSCLC, where the availability of primary tumor tissue is difficult in most patients. In addition, exosomal proteins are protected from proteinase-dependent degradation and thus can be stably detected in the circulating plasma and serum, making them ideal biomarkers for a number of clinical applications. 24, 25 Thus, the present study hypothesized that exosomal proteins are potential diagnostic markers in metastatic NSCLC. To date, proteomic changes of exosomes in body fluid have been described in many malignancies. 26 However, the exosome proteomics of metastatic NSCLC and specific markers from exosomes that distinguish metastatic NSCLC from non-metastatic NSCLC remain less understood. The samples were analyzed as recommended by the manufacturer.
| MATERIALS AND METHODS

| Patients and clinical samples
Protein content of exosomes was determined using a fluorescent microplate reader (Molecular Devices, Biberach an der Riß, Germany), following the manual instructions.
| Statistical analysis
Data were expressed as the median with interquartile range. The data between two groups were compared using the Mann-Whitney U-test and t test. Values of P < .05 were considered to be statistically significant. All statistical analyses were carried out using SPSS 22.0 statistical software.
3 | RESULTS
| Isolation and identification of exosomes
Extracellular vesicles from the serum of patients with NSCLC and healthy donors were isolated by ultracentrifugation, and were called exosomes based on the following observations. Scanning electron microscopy (SEM) showed oval-shaped extracellular vesicles of 50-150 nm diameter ( Figure 1A) . Moreover, the qNano system also showed that the diameter of the exosomes was 50-150 nm ( 
| Profile of proteome in NSCLC cell-derived exosomes
Non-small-cell lung cancer exosomes are enriched in proteins and are implicated in the tumor microenvironment. Studies have shown that they can regulate tumor metastasis. 6 In the present study, patients with distant metastatic disease (bone, brain etc., n = 5), non-metastatic NSCLC (stage I-IIIa, n = 5), and healthy donors (n = 5) were selected as a discovery cohort for proteomic analysis.
F I G U R E 1 Exosome characterization and quantification of total proteins. Mann-Whitney U-test indicated significant differences in total protein levels between the different patient groups. Data are expressed as median with interquartile range. ns, not significant; ****P < .0001. In total, 628 proteins from exosomes were identified, among which 552 proteins were quantified. A quantitative ratio of more than 1.5 was considered upregulation, whereas that less than 0.667 was con- The Samples including metastatic and non-metastatic NSCLC and healthy donors were analyzed using western blotting in an independent patient cohort comprising patients with metastatic NSCLC (n = 51), patients with non-metastatic NSCLC (n = 51), and healthy donors (n = 51). Presence of exosomal marker HSP70 was confirmed by western blotting ( Figure 3A) . Quantitative results showed that patients with metastatic NSCLC showed high expression levels of LBP compared with patients with non-metastatic NSCLC and healthy donors. However, the non-metastatic NSCLC group showed similar exosomal LBP levels to healthy donors ( Figure 3A ).
Concentration of LBP was measured using ELISA in a symptomatic set with 273 subjects to determine whether LBP proteins entered the bloodstream at levels that could be measured and used as cancer biomarkers (Table 3) . Of the 273 individuals, 183 patients with NSCLC (89 metastatic NSCLC and 94 non-metastatic NSCLC) and 90 healthy donors were identified. Median expression level of exosomal LBP in patients with NSCLC and healthy donors was 1.895 ng/mL (range 0.588-3.887 ng/mL) and 0.577 ng/mL (range 0.143-1.138 ng/mL), respectively, with a significant difference (P < .0001; Figure 3D) . Area under the curve (AUC) was 0.713 with a sensitivity of 65% and a specificity of 75.6% ( Figure 3E ). Based on this result, expression level of exosomal LBP from patients with metastatic and non-metastatic NSCLC was further analyzed. Analysis of the validation cohort showed that median expression level of exosomal LBP from patients with metastatic NSCLC and patients with non-metastatic NSCLC was 3.23 ng/mL (range 1.876-5.330 ng/mL) and 0.881 ng/mL (range 0.204-1.994 ng/mL), respectively. Expression level of exosomal LBP in patients with metastatic NSCLC was significantly higher than the level in those with non-metastatic NSCLC (P < .0001; Figure 3D ). Receiver operating characteristic (ROC) curves indicated that exosomal LBP proteins had an AUC of 0.803 with a sensitivity of 83.1% and a specificity of 67% (Figure 3F) . However, no statistically significant difference was found between patients with non-metastatic NSCLC and healthy donors (P = .09; Figure 3D ). Figure 3G ). ROC curves showed an AUC of 0.683 with a sensitivity of 79.5% and a specificity of 47.2% ( Figure 3I ). Moreover, the circulating LBP levels in patients with non-metastatic NSCLC were similar to those in healthy donors (P = .061; Figure 3G ). LBP is an acute-phase protein with a molecular weight of approximately 65 kDa, present in blood at high concentrations, and mainly produced by the liver. [28] [29] [30] It has a variety of biological activities, such as anti-inflammatory effects. 31 Moreover, LBP is reported to be a part of the family of lipid transfer proteins, including cholesterol ester transfer protein and phospholipid transfer protein. 32 In this study, these effects were believed to be regulated by changes in lipid composition and selected phosphatidylethanolamine plasma hormones, sphingolipids, ceramides, sphingomyelin, phosphatidylserine, and glycerolipid. LBP has phospholipid transporter activity. 33 No relevant study is available on the mechanism of action and changes in exosomal LBP in malignant tumors. Based on the results of the present study, exosomal LBP was speculated to be the driving factor of metastatic NSCLC. This study broadened the idea of studying the metastasis of NSCLC. Also, LBP and other differential expression proteins were likely to be important resources for finding new diagnostic biomarkers and potential targets of drugs. However, the study of proteomics of malignant tumor exoplasm is still in its infancy. According to the results of the bioinformatics analysis, the proteins that had a marked change in some specific pathways, biological functions, and developing antibodies specifically against the selected targets were then chosen to validate the selected targets biochemically. An indepth study of exocrine proteomics will help understand the mechanism of action of human exosomes and even the whole-cell vesicle system in tumor development, leading to a better understanding of the clinical application of exosomes. 
| DISCUSSION
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